Τίτλος:
Cardiovascular and renal outcomes of incretin-based therapies: A review of recent clinical trials
Γλώσσες Τεκμηρίου:
Αγγλικά
Περίληψη:
Background: To report the cardiovascular and renal effects of incretin-based therapies. Methods: The studies of clinical trials on incretin-based therapy published in medical journals from the years 2010 to 2017 were comprehensively searched using MEDLINE and EMBASE with no language restriction. The studies were reviewed and the cardiovascular and renal risks reported were recorded. Results: Incretin-based therapeutics represent novel and promising anti-diabetes drugs, the direct cardiovascular actions which may translate into demonstrable clinical benefits on cardiovascular outcomes. Furthermore, incretin-based therapies do not adversely affect renal function. © 2020 Bentham Science Publishers.
Συγγραφείς:
Kyriakos, G.
Quiles-Sanchez, L.V.
Garmpi, A.
Farmaki, P.
Kyre, K.
Gkogkos, S.
Savvanis, S.
Memi, E.
Περιοδικό:
Current Cardiology Reviews
Εκδότης:
Bentham Science Publishers
Λέξεις-κλειδιά:
alogliptin; canagliflozin; cilostazol; dapagliflozin; dipeptidyl peptidase IV inhibitor; empagliflozin; glimepiride; glucagon like peptide 1 receptor agonist; glucose; hemoglobin A1c; incretin; insulin; insulin glargine; insulin lispro; linagliptin; liraglutide; metformin; pioglitazone; ranibizumab; saxagliptin; sitagliptin; sodium glucose cotransporter 2 inhibitor; sulfonylurea; vildagliptin; incretin, cardiovascular disease; cardiovascular risk; chronic kidney failure; clinical trial (topic); diabetes mellitus; diabetic nephropathy; drug efficacy; drug safety; dyslipidemia; end stage renal disease; estimated glomerular filtration rate; glucose blood level; glucose homeostasis; glycemic control; heart failure; heart infarction; human; hypertension; hypoglycemia; insulin blood level; insulin dependent diabetes mellitus; insulin resistance; kidney disease; kidney function; kidney graft; metabolic syndrome X; microalbuminuria; moderate renal impairment; non insulin dependent diabetes mellitus; phase 3 clinical trial (topic); plasma renin activity; randomized controlled trial (topic); renal replacement therapy; Review; risk factor; systematic review; cardiovascular system; drug effect; non insulin dependent diabetes mellitus, Cardiovascular System; Diabetes Mellitus, Type 2; Humans; Incretins
DOI:
10.2174/1573403X15666190603111056
